Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
8,316 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07818304 | SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC(Endouble 2) | not yet recruiting | Phase 2 | 61 | The First People's Hospital of LianyungangOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818486 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT07818499 | A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 204 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07819188 | SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 90 | Sinocelltech Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02960022 | A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | active not recruiting | Phase 2 | 900 | Astellas Pharma Global Development, Inc.INDUSTRY | 38 | Sep 11, 2026 | clinicaltrials |
| NCT04191499 | A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer(INAVO120) | active not recruiting | Phase 2 / Phase 3 | 325 | Hoffmann-La RocheINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
| NCT05123482 | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | recruiting | Phase 1 / Phase 2 | 460 | AstraZenecaINDUSTRY | 15 | Sep 11, 2026 | clinicaltrials |
| NCT05201248 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 49 | GenmabINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06049290 | A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 342 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06247995 | A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.(NeoB-Cap1) | active not recruiting | Phase 1 / Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 11 | Sep 11, 2026 | clinicaltrials |
| NCT06309485 | Phase 2 Study of WGI-0301 for Advanced HCC | recruiting | Phase 2 | 60 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT06526793 | Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL(SOUNDTRACK-B) | recruiting | Phase 2 | 270 | AstraZenecaINDUSTRY | 16 | Sep 11, 2026 | clinicaltrials |
| NCT06535607 | Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors(eVOLVE-02) | recruiting | Phase 2 | 257 | AstraZenecaINDUSTRY | 12 | Sep 11, 2026 | clinicaltrials |
| NCT06634589 | A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 80 | BeOne MedicinesINDUSTRY | 8 | Sep 11, 2026 | clinicaltrials |
| NCT06840002 | A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 150 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07022964 | CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas | recruiting | Phase 1 / Phase 2 | 36 | Beijing GoBroad HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07586943 | SKB118 Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 530 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07812493 | Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement | not yet recruiting | Phase 2 | 24 | Pengpeng XuOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07814859 | Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer | not yet recruiting | Phase 2 | 88 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815223 | A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC | recruiting | Phase 2 | 20 | Yantai Yuhuangding HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815288 | Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases | not yet recruiting | Phase 2 | 80 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815522 | Abiraterone With Dalpiciclib in Salivary Gland Carcinoma | recruiting | Phase 2 | 36 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02135042 | Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | active not recruiting | Phase 2 / Phase 3 | 924 | NRG OncologyOTHER | 8 | Sep 10, 2026 | clinicaltrials |
| NCT04868162 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | completed | Phase 2 | 70 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04993391 | AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 32 | Suzhou Junjing BioSciences Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05027386 | Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study. | completed | Phase 1 / Phase 2 | 125 | Sun Yat-sen UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05316935 | GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients | recruiting | Phase 2 / Phase 3 | 80 | Xiaojun ChenOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05445843 | Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.(KontRASt-06) | active not recruiting | Phase 2 | 95 | Novartis PharmaceuticalsINDUSTRY | 19 | Sep 10, 2026 | clinicaltrials |
| NCT05877820 | A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC | completed | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06379113 | GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients | recruiting | Phase 2 / Phase 3 | 29 | Xiaojun ChenOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06563947 | Oral Fecal Microbiota Transplantation in Advanced Hepatocellular Carcinoma After Progression on ICI-TKI Therapy | recruiting | Phase 2 | 30 | Xu Yong, MDOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06576921 | Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction | active not recruiting | Phase 2 | 116 | Xijing HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06818643 | A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | recruiting | Phase 1 / Phase 2 | 270 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2026 | clinicaltrials |
| NCT06914128 | A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors | recruiting | Phase 1 / Phase 2 | 450 | BayerINDUSTRY | 13 | Sep 10, 2026 | clinicaltrials |
| NCT07231211 | A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 258 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07255872 | A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | recruiting | Phase 2 / Phase 3 | 216 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07638852 | Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.(ABC-R) | recruiting | Phase 2 | 58 | Fudan UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07649421 | PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC(PSMA-DaroRT) | not yet recruiting | Phase 2 | 254 | West China HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811375 | Perioperative Adebrelimab for Locally Advanced Cervical Cancer(ADE-LACC) | not yet recruiting | Phase 2 | 35 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811752 | Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer | recruiting | Phase 2 | 28 | Shanghai Chest HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811986 | HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease(BEYOND-MM 001) | not yet recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812467 | Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 220 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07813390 | Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure(HLA-AML) | enrolling by invitation | Phase 2 | 73 | Guangdong Second Provincial General HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03040973 | Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone | active not recruiting | Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 11 | Sep 9, 2026 | clinicaltrials |
Data updated 16 days agoSource updated unknownsource: clinicaltrials